CJC-1295 DAC 5mg (CJC-1295 DAC)

CJC-1295 DAC is a synthetic peptide analog of growth hormone-releasing hormone (GHRH) designed to enhance the release of growth hormone (GH) in research settings. It is characterized by the inclusion of a Drug Affinity Complex (DAC), which significantly extends its half-life, allowing for sustained GH release over an extended period. This modification is particularly advantageous in research focused on long-term modulation of the GH axis.

The peptide's design aims to mimic the natural pulsatile release of GH, which is crucial for its physiological effects. CJC-1295 DAC has been the subject of various studies exploring its potential applications in understanding growth hormone dynamics, muscle growth, and metabolic processes. However, it is important to note that CJC-1295 DAC is strictly for research purposes and not approved for human consumption.

CJC-1295 DAC functions by binding to the growth hormone-releasing hormone receptor (GHRHR) on the pituitary gland, stimulating the release of growth hormone. The inclusion of the Drug Affinity Complex (DAC) in its structure allows for a prolonged half-life, which can exceed one week, as demonstrated in animal models. This extended half-life is achieved by reversible binding to serum albumin, which protects the peptide from rapid degradation.

Research indicates that this mechanism allows for a more sustained and physiologically relevant pattern of GH release, which is beneficial for studies aiming to replicate natural growth hormone secretion patterns. The ability to maintain elevated GH levels over extended periods without frequent dosing presents a significant advantage in experimental settings.

Studies have shown that CJC-1295 DAC exhibits a significantly longer half-life compared to traditional GHRH analogs due to its DAC modification. In rodent models, the half-life of CJC-1295 DAC has been reported to be approximately 8 days, which is substantially longer than that of non-DAC modified peptides. This prolonged duration of action is attributed to its ability to bind to albumin, reducing renal clearance and proteolytic degradation.

The stability of CJC-1295 DAC in biological systems makes it a valuable tool for research into sustained growth hormone release and its effects on various physiological processes. This stability ensures that the peptide remains active over the course of the study, providing consistent results.

CJC-1295 DAC has been extensively studied for its ability to modulate growth hormone release in research models. Studies in rodents have demonstrated that administration of CJC-1295 DAC leads to a significant increase in circulating levels of GH and insulin-like growth factor 1 (IGF-1), which are critical mediators of growth and metabolism.

The peptide's ability to sustain elevated GH levels without the need for frequent administration makes it a promising candidate for studies investigating the long-term effects of GH on muscle growth, fat metabolism, and overall metabolic health. However, these findings are limited to preclinical models, and further research is needed to fully understand its potential applications.

The unique properties of CJC-1295 DAC make it a valuable tool for a variety of research applications. Its ability to promote sustained GH release has been utilized in studies exploring muscle hypertrophy, recovery, and metabolic regulation. In particular, research in animal models has shown potential benefits in enhancing muscle mass and reducing adiposity.

Additionally, CJC-1295 DAC is being investigated for its role in studying age-related changes in GH secretion and its impact on age-associated diseases. The peptide's long-acting nature provides a model for understanding the chronic effects of GH modulation, which could inform future research directions in endocrinology and metabolism.